Exelixis Q2 Revenue Falls 11 Percent
(NASDAQ:EXEL), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025, beating analyst consensus of $0.66. Revenue totaled $568.3 million, GAAP revenue of $568.3 million was below the analyst estimate of $580.05 million, and Revenue declined 10.8% year-over-year. This shortfall was mainly due to the absence of a $150.0 million milestone recorded in Q2 2024. Solid growth in net product revenue, especially from CABOMETYX for neuroendocrine tumors, showed strong underlying demand. While non-GAAP earnings beat expectations and commercial execution remained strong, headline GAAP revenue was negatively affected by collaboration milestone timing, making for a mixed overall quarter.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
(NASDAQ:EXEL) develops and commercializes therapies for cancer, focusing mostly on targeted small-molecule drugs. The company's core product is cabozantinib, sold as CABOMETYX for kidney, liver, thyroid, and, more recently, neuroendocrine cancers. Exelixis also markets COMETRIQ, another cabozantinib brand.
Source Fool.com
Exelixis Inc. Aktie
Einige Buy-Einschätzungen geben Exelixis Inc. den Vorteil gegenüber Sell-Einschätzungen.
Für Exelixis Inc. ergibt sich ein negatives Potenzial von -7.71%, obwohl das Kursziel von 43 € unter 46.59 € liegt.
